comprehensive -WSS

comprehensive

author：knowledge 2025-08-11 08:01:26 - browse：72399

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： New study raises questions about niacin and heart health

WSS

Abridge raises $150m as clinical notes automation market heats up

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Secretariat’s lessons for human medicine

New study raises questions about niacin and heart health

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Flagship Pioneering startup Sonata Therapeutics lays off 21

focus

comprehensive

focus

Hepatitis C has a cure — but many Americans still lack access to it

Pennsylvania man bitten on the head by bear during attack in his garage

Hollywood unions extend contract negotiations for actors

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare Advantage enrollment hits roughly 33.4 million

The high cost of giving birth even with insurance

Tuberculosis patients need more than just free medication

Malaria cases in Florida and Texas: Here’s what you need to know

NFL doctors' conflicts of interest could endanger players, report says

knowledge

Doctors push to include dialysis machines in emergency stockpile

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

New study raises questions about niacin and heart health

Sage considers ways to reduce costs following FDA rejection

With heat waves through August, officials warn of health risks

Reporting on presidential health from Reagan to Trump and Biden

entertainment

entertainment

focus

knowledge